Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 161

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Anti‐VEGF Aptamer (Pegaptanib) Therapy for Ocular Vascular Diseases

NG, EUGENE W.M., ADAMIS, ANTHONY P.·2006·Annals of the New York Academy of Sciences

Abstract

Abstract: Vascular endothelial growth factor (VEGF) is a central regulator of both physiological and pathological angiogenesis. Pegaptanib, a 28‐nucleotide RNA aptamer specific for the VEGF 165 isoform, binds to it in the extracellular space, leaving other isoforms unaffected, and inhibits such key VEGF actions as promotion of endothelial cell proliferation and survival, and vascular permeability. Pegaptanib already has been examined as a treatment for two diseases associated with ocular neovascularization, age‐related macular degeneration (AMD) and diabetic macular edema (DME). Preclinical studies have shown that VEGF 165 alone mediates pathological ocular neovascularization and that its inactivation by pegaptanib inhibits the choroidal neovascularization observed in patients with neovascular AMD. In contrast, physiological vascularization, which is supported by the VEGF 121 isoform, is unaffected by this inactivation of VEGF 165. In addition, animal model studies have shown that intravitreous injection of pegaptanib can inhibit the breakdown of the blood–retinal barrier characteristic of diabetes and even can reverse this damage to some degree. These preclinical findings formed the basis for randomized controlled trials examining the efficacy of pegaptanib as a therapy for AMD and DME. The VEGF Inhibition Study in Ocular Neovascularization (VISION) trial comprising two replicate, pivotal phase 3 studies, demonstrated that intravitreous injection of pegaptanib resulted in significant clinical benefit, compared with sham injection, for all prespecified clinical end points, irrespective of patient demographics or angiographic subtype, and led to pegaptanib's approval as a treatment for AMD. A phase 2 trial has provided support for the efficacy of intravitreous pegaptanib in the treatment of DME.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1196/annals.1348.062

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 161

Metadata

Authors
NG, E. W. M., & ADAMIS, A. P.
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
2006-10
Volume
1082
Issue
1
Pages
151-171
ISSN
  • 0077-8923 (ISSN-L)
  • 1749-6632
OpenAlex
W2054703112
Cited by
161
References
10
FWCI
7.94
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti‐VEGF Aptamer (Pegaptanib) Therapy for Ocular Vascular Diseases. https://app.cochat.ai/papers/10.1196/annals.1348.062
The paper
NG, E. W. M., & ADAMIS, A. P. (2006). Anti‐VEGF Aptamer (Pegaptanib) Therapy for Ocular Vascular Diseases. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1348.062

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.